Drug content effects on the dispersion performance of adhesive mixtures for inhalation.

by Floris Grasmeijer, Paul Hagedoorn, Henderik W Frijlink, Anne H de Boer
Published 2013-01-01

Prerequisites for a dry powder inhaler for children with cystic fibrosis.

by Anne J Lexmond, Paul Hagedoorn, Henderik W Frijlink, Bart L Rottier, Anne H de Boer
Published 2017-01-01

Effect of inhaler design variables on paediatric use of dry powder inhalers.

by Anne J Lexmond, Tonnis J Kruizinga, Paul Hagedoorn, Bart L Rottier, Henderik W Frijlink, Anne H de Boer
Published 2014-01-01

New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation.

by Floris Grasmeijer, Anne J Lexmond, Maarten van den Noort, Paul Hagedoorn, Anthony J Hickey, Henderik W Frijlink, Anne H de Boer
Published 2014-01-01

Pulmonary immunization: deposition site is of minor relevance for influenza vaccination but deep lung deposition is crucial for hepatitis B vaccination

by Jasmine Tomar, Wouter F. Tonnis, Harshad P. Patil, Anne H. de boer, Paul Hagedoorn, Rita Vanbever, Henderik W. Frijlink, Wouter L.J. Hinrichs
Published 2019-11-01

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients.

by Marcel Hoppentocht, Onno W Akkerman, Paul Hagedoorn, Jan-Willem C Alffenaar, Tjip S van der Werf, Huib A M Kerstjens, Henderik W Frijlink, Anne H de Boer
Published 2016-01-01

Targeting the small airways with dry powder adenosine: a challenging concept

by Erica van der Wiel, Anne J. Lexmond, Maarten van den Berge, Dirkje S. Postma, Paul Hagedoorn, Henderik W. Frijlink, Martijn P. Farenhorst, Anne H. de Boer, Nick H. T. ten Hacken
Published 2017-01-01